Trial PaperDepressive DisordersAnxiety DisordersChronic PainPalliative & End-of-Life DistressLSD

LSD in the supportive care of the terminally ill cancer patient

This open-label case study (1985, n=4) describes the experience of administrating LSD (100-400μg, multiple sessions) in supportive circumstances but without much knowledge of set & setting and effective therapeutic interventions.

Authors

  • Kurland, A. A.

Published

Journal of Psychoactive Drugs
individual Study

Abstract

From the conclusion: In the search for new techniques that might enhance the efficacy of psychotherapy, particularly in those patients whose motivational powers have been weakened or lost, a compound such as LSD may hold considerable promise. This is reinforced by the fact that the experiences in this study indicate that trained personnel can implement the psychedelic procedure with relatively high safety and replicate its major objective, the peak experience, to a degree that makes the phenomenon difficult to sweep under the experimental rug. At the same time, it underscores the need for controlled studies, an objective that may be very difficult to achieve in view of the unique nature of the drug experience and its therapeutic objective.

Available with Blossom Pro

Research Summary of 'LSD in the supportive care of the terminally ill cancer patient'

Introduction

Supportive care for terminal cancer patients often fails to address psychological suffering alongside physical symptoms, and persistent pain plus heavy use of narcotics can restrict awareness and impede psychotherapeutic efforts. Earlier anecdotal and small observational reports suggested that lysergic acid diethylamide (LSD) can alter perception, reduce pain and sometimes produce profound meaningful or mystical experiences that might relieve despair and facilitate communication between dying patients and their families. Prior work cited by the author includes chemotherapeutic use of LSD as an analgesic and literary and clinical accounts that framed mystical states as potentially helpful at the end of life. Kurland and colleagues initiated an experimental programme to evaluate LSD administered within a structured psychotherapeutic framework they term psychedelic peak psychotherapy. The intervention sought to maintain patient awareness while easing depression, anxiety and pain, and to encourage a peak or “psychedelic” experience that could reduce isolation and enhance interpersonal connection. The programme grew from a single unplanned clinical treatment of a staff member and the authors set out to describe their methods, clinical vignettes and impressions of safety and therapeutic effect in terminal cancer patients.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

Related Clinical Trial

Completed

Spring Grove / Maryland Psychiatric Research Center LSD-Assisted Psychotherapy Program for Terminal Cancer (Pahnke, Grof, Richards, Kurland ~1965–1972)

Uncontrolled open pilot clinical series of LSD- and DPT-assisted psychotherapy for terminal cancer patients conducted at Spring Grove State Hospital and the Maryland Psychiatric Research Center, Baltimore MD (~1965–1972; key investigators: Walter Pahnke, Stanislav Grof, William Richards, Albert Kurland). Total n~60 terminal cancer patients by July 1972 (P1 reports n=31 in earlier series; P2/P5 overlap with later cohort). Participants: referred for significant pain, depression, tension, anxiety or psychological isolation; estimated life expectancy ≥3 months. Sessions: single supervised psychedelic session (LSD 200–500 mcg IM, modal 300 mcg; or DPT 60–105 mg parenterally for shorter effect), with male-female therapist dyad, eyeshades, headphones, classical music, family involvement at termination. Preparatory psychotherapy ~6–12 h; integration psychotherapy beginning day after session. Outcome: Pahnke-Richards 7-domain observer rating (depression, isolation, fear of death, pain, etc. −6 to +6) by therapists, nurses, physicians, family; narcotic scale for analgesic use. Repeated sessions permitted if peak experience not achieved or symptoms recurred. No control arm; no registration (pre-registration era). Multiple publications report overlapping cohorts: Pahnke WN (1972, book chapter); Grof S et al. (Int Pharmacopsychiatry 1973, PMID 4140164); Kurland AA (J Psychoactive Drugs 1985, PMID 2418186).

Started
Type
interventional
Randomized
No
Registry ID
SPRING-GROVE-1965-1972-LSD-DPT-TERMINAL-CANCER-PROGRAM

References (2)

Papers cited by this study that are also in Blossom

A review of the clinical effects of psychotomimetic agents

Osmond, H. · Annals of the New York Academy of Sciences (2010)

296 cited

Cited By (18)

Papers in Blossom that reference this study

Classic psychedelics do not affect T cell and monocyte immune responses

Rudin, D., Areesanan, A., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)

Classic psychedelics as therapeutics for psychiatric disorders

Nichols, C. D., Hendricks, P. S. · Handbook of Behavioral Neuroscience (2020)

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

Psychedelics and music: neuroscience and therapeutic implications

Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

Potential Therapeutic Effects of Psilocybin

Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)

Show all 18 papers
Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Lysergic acid diethylamide: a drug of ‘use’?

Das, S., Barnwal, P., Ramasamy, A. et al. · Therapeutic Advances in Psychopharmacology (2016)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Changes in Spirituality Among Ayahuasca Ceremony Novice Participants

Trichter, S., Klimo, J., Krippner, S. · Journal of Psychoactive Drugs (2009)

75 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Hallucinogens

Nichols, D. E. · Pharmacology and Therapeutics (2004)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.